Carbapenem Market Key Players | Spero Therapeutics Inc., Savior Lifetec Corporation, Meiji Seika Pharma Co. Ltd.

Key Highlights:
• The global Carbapenem Market size was valued at USD 4.2 billion in 2022 growing at a CAGR of 4.5% from 2023 to 2033.
• North America dominated the market in 2022
• Asia Pacific is expected to grow at the highest CAGR from 2023 to 2033

As per the study initiated by Evolve Business Intelligence, the global Carbapenem Market size accounted for USD 4.2 Billion in 2022, growing at a CAGR of 4.5% from 2023 to 2033. The carbapenem market is a highly competitive market with a number of generic players entering the market. This competition is expected to drive down prices and make carbapenems more affordable in developing countries. However, the development of new carbapenem formulations and the increasing demand for effective treatment options for MDR infections are expected to support the growth of the market in the long term.

Request/Download PDF Sample: https://report.evolvebi.com/index.php/sample/request?referer=openpr.com&reportCode=021788

The Carbapenem Market is primarily driven by the increasing demand for generic carbapenems. Generic carbapenems are becoming increasingly available, and they are a more affordable option for many patients. This is expected to help to drive growth in the carbapenem market in the coming years.

Key Players
Some of the major Carbapenem Market players holding high market shares include Spero Therapeutics Inc., Savior Lifetec Corporation, Meiji Seika Pharma Co. Ltd., Merck & Co. Inc., Gland Pharma Ltd. These players use partnership and collaboration as a key strategy to gain significant market share to compete with market leaders. Some of the other major market players include Aurobindo Pharma Ltd., Daewoong Pharmaceutical Co. Ltd., Iterum Therapeutics plc, ACS Dobfar S.P.A.

Report Description: https://report.evolvebi.com/index.php/sample/request?referer=openpr.com&reportCode=021788

Segmental Analysis
Based on Product Type, the Carbapenem Market is segmented into Meropenem, Imipenem, Doripenem and Tebipenem. The meropenem segment dominated the market, owing to their broad-spectrum activity against various bacteria, including multidrug-resistant strains.
Based on sales Channel, the Carbapenem Market is segmented into Hospital Pharmacies, Retail Pharmacies & Drug Stores and Online Pharmacies. The hospital pharmacies segment held the largest share of the carbapenem-based antibiotics market. The market for carbapenem-based antibiotics was dominated by the hospital pharmacies sector.

Key Region/ Countries Covered
• North America (US, Canada, Mexico)
• Europe (Germany, U.K., France, Italy, Spain, Russia, Nordic Countries, BeNeLux, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Rest of Asia Pacific)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, South Africa, Rest of MEA)
• Latin America (Mexico, Brazil, Argentina, Rest of Latin America)

Address
Evolve Business Intelligence
C-218, 2nd floor, M-Cube
Gujarat 396191
India
Email: sales@evolvebi.com
Website: https://evolvebi.com/

About EvolveBI
Evolve Business Intelligence is a market research, business intelligence, and advisory firm providing innovative solutions to challenging pain points of a business. Our market research reports include data useful to micro, small, medium, and large-scale enterprises. We provide solutions ranging from mere data collection to business advisory.
Evolve Business Intelligence is built on account of technology advancement providing highly accurate data through our in-house AI-modelled data analysis and forecast tool - EvolveBI. This tool tracks real-time data including, quarter performance, annual performance, and recent developments from fortune's global 2000 companies.

This release was published on openPR.